Today’s healthcare environment is moving rapidly toward greater costs control, making it more and more challenging to bring new therapies to market. Even the most promising pharmaceutical products or medical devices are costly to launch and market, due to the high pricing models used to maximize return on investment and fund future discoveries.
At the same time, reimbursement policies have grown more stringent, creating hurdles for manufacturers, distributors, and specialty pharmacies, as well as providers and patients.
Our speakers will share their experience on the reimbursement environment, issues and latest trends as well as help us better understand how to build value through innovative access & reimbursement strategies and services.
Together with the French-American Chamber of Commerce in San Francisco, swissnex is pleased to bring you this informative joint event in our ongoing series of “Life Science Breakfasts”.
7:30 am breakfast and networking
8:00 am program starts
Speakers: Susanne Machacz, Senior Director, XCenda, Vikrant Karnik, Vice-President LS, Capgemini, and Bruce Quinn, MD, PhD, Senior Health Policy Specialist, Foley Hoag LLP
Susanne, M.P.H., Senior Director, Xcenda, leads the Reimbursement Strategy and Commercialization service line, a specialized group dedicated to conducting payer policy research, strategic reimbursement planning, and payer advocacy efforts to address commercialization challenges and opportunities for pharmaceutical, biotech, and medical device product. She has developed pre-launch and post-launch reimbursement plans for various therapeutic areas including transplant, HIV/AIDS, oncology, diabetes, and obesity. Ms. Machacz has extensive experience addressing coverage and payment issues for public and private payers, and she advises clients on comprehensive reimbursement strategies and tactical implementation, from product planning and market assessment to product launch and ongoing policy development.
Before joining Xcenda, she held positions at a large pharmaceutical company and a health care consulting firm, managing reimbursement and health policy strategy projects. Before her work in pharmaceutical reimbursement, Ms. Machacz was a policy analyst at the Massachusetts Division of Healthcare Finance and Policy. Her responsibilities included developing health care pricing policies, methodologies, and rates related to long-term care services for Medicaid recipients. She is a member of the American Public Health Association. Ms. Machacz received an M.P.H. from Boston University and a B.A. from The University of Pennsylvania.
Dr. Quinn is a national leader in the areas of Medicare coverage and payment, claims, billing, and Medicare contractor reform processes. He is currently Senior Health Policy Specialist at Foley Hoag, Government Strategies Practice, where he is advising companies, providers and venture capital investors to develop and implement successful strategies on Medicare coverage and payment matters for new technologies, with a particular focus on emerging field of molecular diagnostics and personalized medicine, as well as Medicare Administrative Contractor (MAC) reform and its effect on payment policy.
For about five years, Dr. Quinn was the Medicare Part B Program Medical Director for California. Prior to this, he practiced in the Health & Life Sciences division of Accenture and was a physician-scientist at Northwestern University School of Medicine, leading pathology research for Northwestern’s NIH-funded Alzheimer Research Center. He also held academic positions at New York University School of Medicine and UCLA Center for Health Sciences.
Dr. Quinn is licensed to practice medicine in California, New York and Illinois. He is a board Certified medical specialist in Anatomic Pathology/Neuropathology. He holds the degrees of M.D. and Ph.D. from Stanford University, undertook postdoctoral training at M.I.T., and completed his MBA at the Kellogg Graduate School of Northwestern University.